Table 2.
Frequency, number of contributing person-years, and absolute risk of steroid-associated adverse events
| No. patients included in analysisa | Without steroid therapy |
After steroid therapy initiation |
||||
|---|---|---|---|---|---|---|
| No. of events | Person-years | Rate per 1000 patient-years | No. of events | Person-years | Rate per 1000 patient-years | |
| Any SAAEs (n = 884) | 763 | 2806 | 271.9 | 812 | 2649 | 306.5 |
| Single-occurrence events | ||||||
| Hypertension (n = 668) | 289 | 1542 | 187.4 | 182 | 1048 | 173.7 |
| Hyperglycemia (n = 816) | 27 | 2609 | 10.3 | 42 | 2280 | 18.4 |
| Diabetes (n = 828) | 100 | 2414 | 41.4 | 140 | 1778 | 78.7 |
| Overweight (n = 772) | 100 | 2461 | 40.6 | 109 | 1917 | 56.9 |
| Obese (n = 815) | 132 | 2404 | 54.9 | 124 | 1857 | 66.8 |
| Short stature (n = 374) | 24 | 975 | 24.6 | 39 | 1325 | 29.4 |
| Cataracts (n = 874) | 6 | 2785 | 2.2 | 12 | 2577 | 4.7 |
| Glaucoma (n = 884) | 3 | 2787 | 1.1 | 3 | 2642 | 1.1 |
| Osteoporosis (n = 880) | 4 | 2765 | 1.4 | 7 | 2626 | 2.7 |
| Osteonecrosis (n = 884) | 1 | 2805 | 0.4 | 3 | 2643 | 1.1 |
| Psychosis (n = 883) | 0 | 2806 | 0.0 | 3 | 2637 | 1.1 |
| Multiple-occurrence events | ||||||
| Fractures (n = 884) | 8 | 2806 | 2.9 | 26 | 2649 | 9.8 |
| Any infection (n = 884) | 69 | 2806 | 24.6 | 122 | 2649 | 46.1 |
| Pneumonia (n = 884) | 26 | 2806 | 9.3 | 53 | 2649 | 20.0 |
| Septicemia/bacteremia (n = 884) | 9 | 2806 | 3.2 | 22 | 2649 | 8.3 |
| Peritonitis (n = 884) | 1 | 2806 | 0.4 | 12 | 2649 | 4.5 |
| Cellulitis (n = 884) | 33 | 2806 | 11.8 | 35 | 2649 | 13.2 |
SAAE, steroid-associated adverse event.
a
See Supplementary Table S2 for patient inclusion/exclusion by event and steroid exposure.